{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:04:09Z","timestamp":1758945849837,"version":"3.40.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.amjcard.2015.10.012","type":"journal-article","created":{"date-parts":[[2015,10,23]],"date-time":"2015-10-23T15:24:40Z","timestamp":1445613880000},"page":"105-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT])"],"prefix":"10.1016","volume":"117","clinical-trial-number":[{"clinical-trial-number":"nct00000542","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Michael H.","family":"Alderman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry R.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda B.","family":"Piller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2911-6168","authenticated-orcid":false,"given":"Charles E.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Sarah","family":"Baraniuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara L.","family":"Pressel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahshid A.","family":"Assadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula T.","family":"Einhorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Julian","family":"Haywood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekambaram","family":"Ilamathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Oparil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7110-8295","authenticated-orcid":false,"given":"Tamrat M.","family":"Retta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2015.10.012_bib1","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint national Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC-7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2015.10.012_bib2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2015.10.012_bib3","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2015.10.012_bib4","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2015.10.012_bib5","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/archinternmed.2009.60","article-title":"ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses","volume":"169","author":"Wright","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2015.10.012_bib6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/HCO.0b013e32833a8828","article-title":"ALLHAT: still providing correct answers after 7 years","volume":"25","author":"Einhorn","year":"2010","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.amjcard.2015.10.012_bib7","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone\u2014The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"283","author":"Furberg","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2015.10.012_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.HYP.0000086521.95630.5A","article-title":"Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"42","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.amjcard.2015.10.012_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/01.HYP.37.1.19","article-title":"Baseline characteristics of the 42,448 high risk hypertensive enrolled in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"37","author":"Grimm","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.amjcard.2015.10.012_bib10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/0895-7061(96)00037-4","article-title":"Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT)","volume":"9","author":"Davis","year":"1996","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.amjcard.2015.10.012_bib11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1751-7176.2011.00568.x","article-title":"Mortality and morbidity during and after the antihypertensive and lipid-lowering treatment to prevent heart attack trial","volume":"14","author":"Cushman","year":"2012","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.amjcard.2015.10.012_bib12","unstructured":"Antihypertensive and lipid-lowering treatment to prevent heart attack trial protocol. Available at: https:\/\/allhat.sph.uth.tmc.edu\/Forms\/protocol.pdf. Accessed on May 4, 2015."},{"key":"10.1016\/j.amjcard.2015.10.012_bib13","unstructured":"Extension protocol: antihypertensive and lipid-lowering treatment to prevent heart attack trial. Available at: https:\/\/allhat.sph.uth.tmc.edu\/Forms\/ExtensionProtocol.pdf. Accessed on May 4, 2015."},{"key":"10.1016\/j.amjcard.2015.10.012_bib14","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMra054415","article-title":"Assessing kidney function\u2014measured and estimated glomerular filtration rate","volume":"354","author":"Stevens","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2015.10.012_bib15","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/archinte.165.12.1401","article-title":"Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"Whelton","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2015.10.012_bib16","first-page":"39","article-title":"ALLHAT: setting the record straight","volume":"141","author":"Davis","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2015.10.012_bib17","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2015.10.012_bib18","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2015.10.012_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1741-7015-10-33","article-title":"Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis","volume":"10","author":"Fretheim","year":"2012","journal-title":"BMC Med"},{"key":"10.1016\/j.amjcard.2015.10.012_bib20","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1161\/CIRCULATIONAHA.105.544031","article-title":"Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","volume":"113","author":"Davis","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2015.10.012_bib21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ahj.2006.10.012","article-title":"The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) heart failure validation study: diagnosis and prognosis","volume":"153","author":"Einhorn","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2015.10.012_bib22","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1161\/CIRCULATIONAHA.107.762229","article-title":"Heart failure with preserved and reduced left ventricular ejection fraction in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack trial","volume":"118","author":"Davis","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2015.10.012_bib23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1161\/CIRCOUTCOMES.111.962522","article-title":"Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study","volume":"5","author":"Barzilay","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.amjcard.2015.10.012_bib24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2015.10.012_bib25","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0140-6736(00)02527-7","article-title":"Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)","volume":"356","author":"Brown","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2015.10.012_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2015.10.012_bib27","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A\u00a0calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914915020895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914915020895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T07:55:55Z","timestamp":1537257355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914915020895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0002914915020895"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2015.10.012","relation":{},"ISSN":["0002-9149"],"issn-type":[{"type":"print","value":"0002-9149"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT])","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2015.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}